CD274 and neoplasm: Other biomarkers such as tumor-infiltrating lymphocyte (TIL) and tumor mutational burden (TMB) can also be tested to assess tumor response to immunotherapy, and could be included with PD-L1 testing in next-generation sequencing (NGS) to assess tumor response to other agents in most solid tumors [32,33].